ACCESS MEDICAL LABS

5151 CORPORATE WAY
JUPITER, FL 33458-3101
(866)720-8386

Client: **ACCESS MEDICAL LABORATORI** 1 5151 CORPORATE WAY JUPITER, FL 33458 Phys: (561) 745-1233	Patient: **SAMPLE 6, TEST** Room# DOB. 01/01/1970 Age:47 Sex:F Phone: ( ) - Fasting: N ID#: A1710001391470 Route#: 0 Page:1

Acc# **001391470**	Coll. Date: 10/23/17	Recv. Date: 10/23/17	Print Date: 02/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:05:50 PM	Print Time: 13:50
First reported on:	10/24/17	Final report date:	10/24/17

Test Name	Results	Normal Range	Units
Report Status: FINAL			
COMPLETE BLOOD COUNT			
WHITE BLOOD CELL	5.0	3.9 - 11.4	K/ul
RED BLOOD CELL	5.0	3.80 - 5.50	M/ul
HEMOGLOBIN	15	11.5 - 15.2	g/dl
HEMATOCRIT	45	34.0 - 47.0	%
MCV	90	80.0 - 100.0	fl
MCH	30	26.0 - 34.0	pg
MCHC	33	31.0 - 37.0	g/dl
RDW	15.0	11.0 - 15.5	%
PLATELET COUNT	250	140 - 400	k/ul
MPV	10	7.5 - 11.6	fl
GENERAL CHEMISTRY			
GLUCOSE	100	65 - 100	mg/dl
BUN	20	6 - 20	mg/dl
CREATININE, SERUM	**1.2 H**	0.4 - 1.1	mg/dl
SODIUM	**150 H**	133 - 145	mmol/L
POTASSIUM	5.0	3.3 - 5.1	mmol/L
CHLORIDE	**110 H**	96 - 108	mmol/L
CO2	23	22 - 32	mmol/L
CALCIUM	9.0	8.5 - 10.5	mg/dl
TOTAL PROTEIN	**9.0 H**	6.4 - 8.3	g/dl
ALBUMIN	4.2	3.2 - 4.8	g/dl
GLOBULIN	**4.8 H**	2.2 - 3.7	g/dl
BILIRUBIN, TOTAL	**2.0 H**	0.0 - 1.0	mg/dl
ALKALINE PHOSPHATASE	23	11 - 134	U/L
ALT	25	<32	U/L
AST	26	0 - 32	U/L
Albumin/Globulin Ratio	0.9	0.8 - 2.0	
BUN/CREAT RATIO	N/A	7.3 - 21.7	
GFR, estimated	51		ml/min

If African-American result is: >60

Calculation of estimated GFR is based on the MDRD Study prediction equation

****Five Stages of Chronic Kidney Disease****

Stage	*GFR Level*	*Description*
Stage 1	90 ml/min or more	Healthy Kidneys or Kidney damage with normal or high GFR
Stage 2	60 to 89 ml/min	Kidney damage and mild decrease

(Continued on Next Page)

ACCESS MEDICAL LABS

5151 CORPORATE WAY
JUPITER, FL 33458-3101
(866)720-8386

Client: **ACCESS MEDICAL LABORATORI** 1 5151 CORPORATE WAY JUPITER, FL 33458 Phys: (561) 745-1233	Patient: **SAMPLE 6, TEST** Room# DOB. 01/01/1970 Age:47 Sex:F Phone: ( ) - Fasting: N ID#: A1710001391470 Route#: 0 Page:2

Acc# **001391470**	Coll. Date: 10/23/17	Recv. Date: 10/23/17	Print Date: 02/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:05:50 PM	Print Time: 13:50
First reported on:	10/24/17	Final report date:	10/24/17

Test Name	Results	Normal Range	Units
GENERAL CHEMISTRY (Continued)			
		in GFR	
Stage 3	30 to 59 ml/min	Moderate decrease in GFR	
Stage 4	15 to 29 ml/min	Severe decrease in GFR	
Stage 5	< 15 ml/min	Kidney failure, or on dialysis	
IRON/ANEMIA EVALUATION			
FERRITIN	51	13 - 300	ng/ml
CORONARY RISK			
TRIGLYCERIDES	100	<150	mg/dl
CHOLESTEROL, TOTAL	198	<200	mg/dl
HDL CHOLESTEROL	55	>40	mg/dl
LDL CHOLESTEROL, calc.	**123 H**	<100	mg/dl
CHOL/HDL RATIO	3.6	<4.4	
	The higher the Ratio,the higher CHD risk.		
CRP, Cardio	**31 H**	<3.0	mg/L
	Risk of Cardiovasular Disease		
Low Risk		CRP < 1.0	mg/L
Medium Risk		CRP 1.0 - 3.0	mg/L
High Risk		CRP > 3.0	mg/L
THYROID TESTING			
T3, FREE	**35 H**	1.8 - 4.6	pg/ml
T4, FREE	**12 H**	0.9 - 1.7	ng/dl
TSH	**16 H**	0.27 - 4.2	uIU/ml
ENDOCRINE EVALUATION			
FSH	35	1.7 - 134.8	mIU/ml
Men		1.5 - 12.4	mIU/ml
Women			
Follicular Phase		3.5 - 12.5	,,
Ovulation Phase		4.7 - 21.5	,,
Luteal Phase		1.7 - 7.7	,,
Postmenopause		25.8 - 134.8	,,

(Continued on Next Page)

5151 CORPORATE WAY
JUPITER, FL 33458-3101
(866)720-8386

Client: **ACCESS MEDICAL LABORATORI** 1 5151 CORPORATE WAY JUPITER, FL 33458 Phys: (561) 745-1233	Patient: **SAMPLE 6, TEST** Room# DOB. 01/01/1970 Age:47 Sex:F Phone: ( ) - Fasting: N ID#: A1710001391470 Route#: 0 Page:3

Acc# **001391470**	Coll. Date: 10/23/17	Recv. Date: 10/23/17	Print Date: 02/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:05:50 PM	Print Time: 13:50
First reported on:	10/24/17	Final report date:	10/24/17

Test Name	Results	Normal Range	Units
ENDOCRINE EVALUATION (Continued)			
LH	15	1.0 - 95.6	mIU/ml
Men		1.7 - 8.6	mIU/ml
Women			
Follicular Phase		2.4 - 12.6	,,
Ovulation Phase		14.0 - 95.6	,,
Luteal Phase		1.0 - 11.4	,,
Postmenopause		7.7 - 58.5	,,
PROGESTERONE	23		ng/mL
Women Reference Ranges			
Follicular Phase		0.057 - 0.893	ng/mL
Ovulation Phase		0.121 - 12.0	ng/mL
Luteal Phase		1.83 - 23.9	ng/mL
Postmenopause		<0.05 - 0.126	ng/mL
Pregnant			
1st trimester		11.0 - 44.3	ng/mL
2nd trimester		25.4 - 83.3	ng/mL
3rd trimester		58.7 - 214	ng/mL
As of 09/23/16 Access Medical Labs will be reporting Progesterone using an updated Progesterone Generation-III reagent from Roche. Progesterone-III reduces cross-reactivity, shows higher specificity toward Progesterone and has been traced to the LC/MS reference method. Although results may vary from the previous method, these changes are taken into account in the updated reference ranges.			
ESTRADIOL (E2)	15		pg/ml
Women Reference Ranges			
Follicular Phase		12.5 - 166	pg/ml
Ovulation Phase		85.8 - 498	pg/ml
Luteal Phase		43.8 - 211	pg/ml
Postmenopause		<5.0 - 54.7	pg/ml
Pregnancy			
1st trimester		215 - >4300	pg/ml
Fulvestrant (Faslodex)Cross Reactivity: Fulvestrant therapy will cause false elevated Estradiol Result with this method. Use LC/MS method if patient is on Fulvestrant to avoid Cross reactivity.			
DHEA-SULFATE	**35 L**	35.4 - 256.0	ug/dl

(Continued on Next Page)

5151 CORPORATE WAY
JUPITER, FL 33458-3101
(866)720-8386

Client: **ACCESS MEDICAL LABORATORI** 1 5151 CORPORATE WAY JUPITER, FL 33458 Phys: (561) 745-1233	Patient: **SAMPLE 6, TEST** Room# DOB. 01/01/1970 Age:47 Sex:F Phone: ( ) - Fasting: N ID#: A1710001391470 Route#: 0 Page:4

Acc# **001391470**	Coll. Date: 10/23/17	Recv. Date: 10/23/17	Print Date: 02/22/19
Chart#	Coll. Time: 00:00 AM	Recv. Time:05:50 PM	Print Time: 13:50
First reported on:	10/24/17	Final report date:	10/24/17

Test Name	Results	Normal Range	Units
ENDOCRINE EVALUATION (Continued)			
TESTOSTERONE, TOTAL	**3514 H**	6 - 82	ng/dl
SEX HORMONE BIND GLOBULIN	**135 H**	20 - 130	nmol/L
TESTOSTERONE, FREE	**47.56 H**	0.2 - 2.6	ng/dl
IGF-1	**53 L**	119 - 166	ng/mL

Access Medical Laboratories uses Siemens Healthcare Diagnostics as the supplier for IGF-1 Immunoassay Testing System. Siemens Introduced a Restandardization of IGF-1 assay using WHO 1st International Standard (IS),NIBSC Code 02/254.

Starting 01/25/2017 we will be implementing the new restandardized IGF-1 assay for testing Patients. New Reference Ranges will reflect expected lower values for patient IGF-1 results.

END OF REPORT